Results 201 to 210 of about 88,182,083 (298)

Antenatal Exposure to Medication for Opioid Use Disorder and Infant Outcomes in the Eat, Sleep, Console for Neonatal Opioid Withdrawal Randomized Controlled Trial. [PDF]

J Pediatr
Beauman SGS, Hu Z, Rice W, Devlin L, Merhar SL, Fung CM, Brown J, Osman A, Pahl A, Ramsey KW, Whalen B, MacMillan KDL, Ounpraseuth ST, Das A, Crawford MM, Trochinski L, Greenberg RG, Smith PB, Young LW, Maxwell JR, Eunice Kennedy Shriver NICHD Neonatal Research Network and the NIH ECHO Program IDeA States Pediatrics Clinical Trials Network.   +20 more
europepmc   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Medication for opioid use disorder among adolescents entering specialty treatment for opioid use disorder and trends in the US, 2017-2022. [PDF]

Addict Behav
Boggis JS, Sweeney T, Marsch LA, Marrero WJ, Feder KA, Moen EL.   +5 more
europepmc   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Characteristics of Veterans Receiving Medication for Opioid Use Disorder: An Observational Cohort Study. [PDF]

J Gen Intern Med
Jones KF, Mandavia AD, Gurewich D, Wyse JJ, Sung ML, Becker WC, Livingston NA.   +6 more
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Emergency Department-Based Medication for Opioid Use Disorder: A 5-Year Experience. [PDF]

J Am Coll Emerg Physicians Open
Seaberg DC, McKinnon J, Haselton L, Reuter Q, Kolb J, Vellanki S, Morah JC, Oskvarek J, Jouriles N.   +8 more
europepmc   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Substance-induced mental disorders and discontinuation of medication for opioid use disorder. [PDF]

Drug Alcohol Depend
Tilhou AS, Grucza RA, Xu KY.
europepmc   +1 more source

The psychometric properties of validated tools to assess cannabis use disorder: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung, Daniel Stjepanovic, Stephanie Fong, Danielle Dawson, Giang Vu, Tesfa Yimer, Caitlin McClure‐Thomas, Wayne Denis Hall, Gary Chung Kai Chan   +8 more
wiley   +1 more source